SK-MEL-30 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses wildtype B-Raf and mutant N-Ras (Q61K).
This cell line was established in 1975 from a soft-tissue metastatic site (dermis) in a 66-year-old Caucasian male.
- Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
- Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Carey TE et al. (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proceedings of the National Academy of Sciences 73: 3278-3282 (Pubmed ID: 1067619)
- Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4): 446-457 (Pubmed ID: 21725359)
This cell line may be licensed nonexclusively for research or commercial purposes.